Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter and year ended 30th June 2026, with revenue from operations increasing by 26% YoY to Rs.2150 Cr. Profit After Tax at Rs. 173 Cr, up 12% YoY, and EBITDA pre R&D increased to Rs. 523 Cr; margin stood at 24%. The company reported robust growth in India Branded Business, US Formulation, and API Business.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd announced its unaudited financial results for Q1 FY27, with revenue increasing by 26% YoY to INR 21.50 Bn, driven by 49% YoY growth in US Formulation and 33% YoY growth in API. EBITDA margin improved to ~24%, with a 7% YoY growth in EBITDA before R&D. The company reported a 33% YoY growth in PAT to INR 1.73 Bn, supported by a strong order book.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 173.07 crores and earnings per share of Rs. 8.80.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June, 2026, with a revenue from operations of Rs. 2,149.77 crores and a profit for the period of Rs. 173.07 crores.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has received USFDA final approval for Prucalopride Tablets, 1 mg and 2 mg, a treatment for chronic idiopathic constipation in adults, with an estimated market size of $100 million.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced a conference call to discuss its Q1 FY27 unaudited financial results on August 4, 2026. The call will be held at 5:30 P.M. IST and can be accessed through a registration link or by dialing into a conference line.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 to consider and approve Unaudited Financial Results for the quarter ended 30th June, 2026.